Erica Stringer-Reasor, MD, discusses the leptomeningeal metastases in patients with breast cancer and an FDA-approved targeted therapy/chemotherapy combination that is being studied as a treatment.
Erica Stringer-Reasor, MD, an assistant professor of medicine at the University of Alabama at Birmingham, discusses the leptomeningeal metastases in patients with breast cancer and an FDA-approved targeted therapy/chemotherapy combination that is being studied as a treatment.
0:07 | Leptomeningeal metastasis is a rare but aggressive form of breast cancer with very limited treatment options. There are not many randomized studies or single arm studies evaluating this purely due to the rareness of this disease.
0:24: | We definitely know that as we treat patients with her to targeted therapies, it will treat their body systemically. But eventually they will help a CNS relapse, and we thought it would be important to investigate this and a small cohort of patients and a combination that was recently approved by the FDA for metastatic breast cancer, as well as specifically patients diagnosed for brain metastases. Again, this combination has not been evaluated in left on meninggeal disease.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More